Review

The Impact of Diabetes Mellitus on Cardiovascular Risk Onset in Children and Adolescents

Ida Pastore [1], Andrea Mario Bolla [1], Laura Montefusco [1], Maria Elena Lunati [1], Antonio Rossi [1], Emma Assi [2], Gian Vincenzo Zuccotti [3] and Paolo Fiorina [1,2,4,*]

[1] Division of Endocrinology, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy; ida.pastore@asst-fbf-sacco.it (I.P.); andrea.bolla@asst-fbf-sacco.it (A.M.B.); montefusco.laura@asst-fbf-sacco.it (L.M.); mariaelena.lunati@asst-fbf-sacco.it (M.E.L.); rossi.antonio@asst-fbf-sacco.it (A.R.)

[2] International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science L. Sacco, University of Milan, 20157 Milan, Italy; emma.assi@unimi.it

[3] Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano and Department of Pediatrics, Buzzi Children's Hospital, 20157 Milan, Italy; gianvincenzo.zuccotti@unimi.it

[4] Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA

[*] Correspondence: paolo.fiorina@childrens.harvard.edu; Tel.: +1-617-919-2624

check for updates

Abstract: The prevalence of diabetes mellitus is rising among children and adolescents worldwide. Cardiovascular diseases are the main cause of morbidity and mortality in diabetic patients. We review the impact of diabetes on establishing, during childhood and adolescence, the premises for cardiovascular diseases later in life. Interestingly, it seems that hyperglycemia is not the only factor that establishes an increased cardiovascular risk in adolescence. Other factors have been recognized to play a role in triggering the onset of latent cardiovascular diseases in the pediatric population. Among these cardiovascular risk factors, some are modifiable: glucose variability, hypoglycemia, obesity, insulin resistance, waist circumference, hypertension, dyslipidemia, smoking alcohol, microalbuminuria and smoking. Others are unmodifiable, such as diabetes duration and family history. Among the etiological factors, subclinical endothelial dysfunction represents one of the earliest key players of atherosclerosis and it can be detected during early ages in patients with diabetes. A better assessment of cardiovascular risk in pediatric population still represents a challenge for clinicians, and thus further efforts are required to properly identify and treat pediatric patients who may suffer from cardiovascular disease later in early adulthood.

Keywords: diabetes mellitus; children; adolescents; cardiovascular risk

1. Introduction

The prevalence of the two most common forms of diabetes, type 1 (T1D) and type 2 (T2D) is increasing worldwide, even in the pediatric population, rapidly becoming an urgent public health problem [1–3]. The International Diabetes Federation has estimated that T1D affects more than 1,100,000 children and adolescents, with an annual incidence of about 128,900 worldwide [1]. Until the early 1990s, T2D was believed to be almost an exclusive condition of adulthood, but its prevalence in adolescents is increasing in many countries [1]. Even if the estimates are not as precise as for T1D, in the United States, 20,262 adolescents are diagnosed with T2D, and by 2050, a fourfold increase will occur [3,4]. In addition, prediabetes affects nearly 5% of children aged between 6 and 10 years [5]. These growing trends are largely due to the spread of a more western lifestyle. Physical inactivity, increased calorie intake and reduced energy expenditure all facilitate overweight and obesity onset in children [6]. These conditions affect almost all children with T2D, and are common also in the

pediatric population, with T1D having a prevalence of up to 34% [7–9]. A recent study was conducted in a population of 708 children who were positive for one of the circulating diabetes autoantibodies, but were not diabetic. The study revealed that the children who tested negative for HLA haplotypes predisposing to T1D and had an elevated body mass index (BMI) progressed to multiple autoantibodies positivity and had an increased risk of developing T1D [10]. Younger patients with T2D showed an impaired insulin secretion and detectable circulating autoantibodies [11,12]. Moreover, children and adolescents with T2D, when compared to adults with T2D, showed a higher and faster loss of beta-cells activity, which makes achieving optimal metabolic compensation more difficult [13–15].

Childhood and adolescence are crucial stages of life for the onset of cardiovascular (CV) risk factors [16]. There is a large body of evidence that suggests that the prevalence of CV risk factors among diabetic children and adolescents is high and, in most cases, these factors are present already at the time of diagnosis [8]. Diabetes mellitus is associated with a two-fold increase in the risk for cardiovascular disease, with a premature CV mortality and a four-fold increase in mortality for all-cause in young [17–19]. Moreover, the coexistence of obesity further increases the risk for specific- and all-cause mortality [20]. Previous studies in T1D and T2D, although not conclusive, suggested an increased risk for ischemic heart, macrovascular diseases and death, particularly in patients with T2D diagnosed between 15 and 30 years of age [21]. A longitudinal cohort of 6.840 patients with T1D, and 1.518 patients with T2D, showed an excess mortality in patients with T2D aged between 15 to 19 when compared to the general population [22]. Moreover, in patients with T1D, CV outcomes and mortality inversely correlate with age at diabetes onset; thus suggesting that the earlier the onset, the greater the risk [18]. The prevalence of two or more CV disease risk factors is higher in younger patients with T2D (92%) than those with T1D (14%), and is increased by 1.4% on an annual basis, over the ten years of the study period, in patients with T2D, but not in those with T1D [23,24]. In line with the aforementioned study, Dabalea et al. demonstrated that 72% of 272 young patients with T2D, contrasting only 32% of 1746 young patients with T1D, developed diabetic complications [25]. The role of hyperglycemia in establishing cardiovascular risk in the short-term might not be as clinically evident in children and adolescents with diabetes when compared to adults with diabetes, partially due to the greater potential regenerative capacity and to the higher number of circulating endothelial progenitor cells in the young [26]. However, in the long-term, evidence suggests a more detrimental role of diabetes when present at a younger age in making patients more vulnerable to cardiovascular CV risks later in life [18].

2. CV Risk Factors in Children and Adolescents with Diabetes

There are several old and new CV risk factors that appear to be relevant for pediatric patients with diabetes and that can be targeted. We classify them as modifiable and unmodifiable factors (Table 1). Among those unmodifiable factors are the age at onset and the disease duration [18,21,24,27]. A large longitudinal study comprising 27,195 patients with T1D and 135,178 controls, proved that mortality for CV disease and for all-cause inversely correlates with the onset age of T1D [18]. Moreover, patients diagnosed before 10 years of age showed a reduced life expectancy of nearly 18 years for women and 14 years for men [18]. Similarly, an early onset of T2D worsens CV risk, and younger patients with T2D are exposed to higher rates of diabetic micro- and macro-vascular complications [21,25]. As the duration of the disease increases, the prevalence of CV risk factors, CV disease death, myocardial infarction, revascularization, angina and stroke rises as well [24,27]. Contrary to what has been reported for the adult population whereby the female gender is associated with a lower CV risk in pre-menopausal period, data from recent literature reported similar CV risk rates in males and females [27–29]. Several modifiable CV risk factors are related to anthropometric measurements and metabolic control [30]. Increased BMI and waist circumference are described in children and adolescents with diabetes, while elevated levels of HbA1c are positively correlated with increased macrovascular complications [1,24,27,31]. Recently, increased glucose variability, which refers to the number and the amplitude of blood glucose fluctuations, more than the mean glycemia or the HbA1c,

has been suggested to be a novel CV risk factor [32,33]. A reduction in glucose variability in young patients, with T1D by using continuous subcutaneous insulin infusion and real time continuous glucose monitoring, ameliorates endothelial function by increasing the flow-mediated dilatation of the brachial artery [34]. Another modifiable risk factor is hypoglycemia. Indeed, Fahrmann et al. showed that severe hypoglycemia positively correlates, regardless of age, with coronary artery calcification in the sub-cohort of patients enrolled in DCCT/EDIC study [35]. Insulin resistance is common to both T1D and T2D, although its pathophysiology seems to be different in youth with T1D, as compared to those with T2D [36]. The simultaneous presence of insulin resistance and T1D has been defined as "hybrid or double diabetes" and patients with T1D and insulin resistance own a more elevated CV risk among patients with T1D [37]. The control of other abnormalities associated with diabetes is of paramount importance. For instance, the importance of assessing blood pressure is supported by the observation that children with T1D with elevated systolic blood pressure had increased carotid intima-media thickness [38]. The prevalence of microalbuminuria, another modifiable risk factor, increases proportionally in youth with T2D, together with the disease duration [39], while in youth with T1D, this mainly correlates with elevated arterial stiffness [40]. In youth with diabetes, a more atherogenic lipid profile directly correlates with glycated hemoglobin, fasting glucose, age, disease duration and the presence of insulin resistance. Many of the aforementioned factors may be associated with a reduced nitric oxide availability [30,41–44]. Finally, the role of smoking and alcohol as CV risk factors in adulthood is well known, even if their long-term effects in adolescents have not been clarified yet [45].

Table 1. Modifiable and Unmodifiable Cardiovascular Risk Factors in Children and Adolescents with Diabetes.

Modifiable Risk Factors	Unmodifiable Risk Factors
Obesity	Younger age at diabetes onset
Waist circumference	Diabetes duration
Insulin resistance	Family history
Hyperglycemia	
Hypoglycemia	
Glucose variability	
Hypertension	
Microalbuminuria	
Dyslipidemia	
Smoking	
Alchol	

3. Inflammation in Children and Adolescents with Diabetes

An early appearance of a pro-inflammatory state may be a key player in conditioning the onset of CV disease later in life [46]. Central obesity and physical inactivity are both associated with a pro-inflammatory state and are very common in young patients with obesity, with T2D and with T1D [9,11,13,42,47]. Obesity and T2D are characterized by a state of systemic chronic low-grade inflammation, that triggers a vicious circle involving insulin resistance, oxidative stress and endothelial dysfunction and lays the basis for early and accelerated atherosclerosis [46]. A low-grade inflammation is also observed in lean children with T1D, while increased levels of pro-inflammatory cytokines are described, either in T1D or T2D [48,49]. Continuous systemic chronic inflammation from childhood accelerates plaque formation and contributes to its growth [48]. Nearly 700 adolescents aged between 10 and 17 years who had a recent diagnosis of T2D were studied, and a detrimental inflammatory profile that worsened over time was shown [50]. Indeed, the inflammatory state was only partially reverted by pharmacological therapy [50]. In children and adolescents with diabetes, pro-inflammatory abnormalities may play a prognostic role for the development of diabetic complications and may represent novel pharmacological targets [51]. Previous studies, although not conclusive, demonstrated increased levels

of C-reactive protein, interleukin-6, tumor necrosis factor-α, leptin, and decreased levels of adiponectin in children and adolescents with diabetes [52–57]. Interestingly, pro-inflammatory marker levels seem to also be elevated in lean adolescents with diabetes and good glycemic control [58,59]. Interestingly, the role of diet in modifying the inflammatory profile in children with diabetes is still debated; while in children with obesity, it only seems to be more evident [60,61]. More recently, a putative role for microbiome in the activation of gut and systemic inflammation was suggested in children and adolescents with diabetes [62]. This is of particular interest, especially in children and adolescents in which a pro-inflammatory state may persist over time, and may exert a detrimental effect on the CV system [46]. Interventional studies on the effect of prebiotics on gut microbiota are needed to elucidate their role in improving inflammatory state, insulin resistance and glycemic control.

4. Endothelial Dysfunction in Children and Adolescents with Diabetes

Even if not entirely well elucidated in their mechanisms, vascular complications are the results of direct action of hyperglycemia, but also of abnormalities of other mediators such as proinflammatory cytokines, growth factors, advanced glycation end-products (AGEs) and cell adhesion molecules [63,64]. Endothelial injury may represent the earlier phenomenon of vascular dysfunction, and hyperglycemia is probably the main driver of endothelial injury in children [65]. Hyperglycemia increases the production of reactive oxygen species and of AGEs, activates the protein kinase C, hexosamine and polyol pathways and affects the function of endothelial progenitor cells [51,66,67]. A growing number of studies showed increased inflammation and endothelial dysfunction in children and adolescents with diabetes, which was then associated with an increased CV risk (Table 2).

Children and adolescents with T1D showed elevated levels of the highly sensitive C-reactive protein when compared to healthy subjects [53,68]. In children and adolescents with diabetes, an increased level of serum intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 was observed [47,55,69–71]. Levels of E-selectin are augmented in children and adolescents with T1D and are associated with systolic and diastolic blood pressure abnormalities [69,72]. Furthermore, high levels of circulating endothelial cells in children and adolescents with T1D positively correlated with HbA1c levels [53]. Increased levels of tumor necrosis factor-α were observed in young patients with T1D and T2D, and high interleukin-6 levels were observed in those with T1D [54,55,70,73]. Unfortunately, the clinical significance of these biomarkers must still be proven, and their use in epidemiological studies still needs to be explored. In this view, the early detection of endothelial dysfunction in children and adolescents with diabetes might be useful to prevent, or at least delay, cardiovascular complications [74].

5. Cardiac Dysfunction in Children and Adolescents with Diabetes

Diabetic cardiomyopathy comprises both functional and structural changes of the myocardium, regardless of hypertension, ischemic or valvular heart disease, and it can occur either as a systolic or diastolic dysfunction [75]. Hyperglycemia leads to the increased tissue deposition of AGEs that crosslink with proteins of the extracellular matrix, resulting in fibrosis and myocardial tissue remodeling [76]. The role of hyperglycemia in initiating and maintaining left ventricular diastolic dysfunction is supported by the observation that, in patients undergoing combined kidney and pancreas transplantation, no longer requiring insulin administration, a reversal of diastolic dysfunction was observed [77]. Endothelial dysfunction and vascular stiffness precede diastolic dysfunction, and their early recognition and treatment may prevent or delay diastolic dysfunction [78]. As left ventricular diastolic dysfunction represents the earliest manifestation of the diabetic cardiomyopathy that anticipates systolic dysfunction, several studies revealed diastolic dysfunction still in the presence of a normal left ventricular ejection fraction [77,79]. Children and adolescents with diabetes manifested subclinical ventricular abnormalities, when studied with both conventional or novel tissue Doppler echocardiography, and compared with healthy controls [80–82]. Moreover, concentric left ventricular hypertrophy is common among adolescents

with diabetes, especially in those with obesity, identified by the increase of left ventricular wall thickness over time [82].

Children and adolescents with a recent onset of T1D showed the same cardiac function of healthy peers [83]. In a prospective cross-sectional study, it has been demonstrated that effectively controlled children and adolescents with long-term T1D showed diastolic dysfunction and subclinical systolic dysfunction, regardless of a normal left ventricular ejection fraction, and both of these abnormalities are associated with disease duration [81]. Cardiac functional abnormalities are associated with BMI in children and adolescents with and without diabetes, suggesting that the control of obesity is mandatory to prevent cardiac disease, especially in those with diabetes in which the progression of cardiac abnormalities seems accelerated [82,84,85]. In children with T1D, cardiac dysfunction seems to be influenced by disease duration, poor glycemic control, microalbuminuria, retinopathy and increased blood pressure [83,86,87]. Left ventricular performance has also been studied during physical activity sessions in adolescents with and without diabetes and, as expected, those with T1D or T2D showed a lower exercise tolerance compared to healthy controls [88,89]. Interestingly, a structured physical activity program over time is able to ameliorate physical training tolerance in adolescents with and without diabetes, but the level of cardiac performance remains lower in those with diabetes [89,90]. Nevertheless, these observations confirm the essential role of physical exercise in a necessarily modified lifestyle, adapted for the prevention of CV disease, especially in the high-risk CV population [89].

6. Vascular Tests to Unveil Early CV Risk in Children and Adolescents with Diabetes

Several surrogate indices are used in clinical practice to assess early vascular abnormalities (Table 3). Young patients with T1D showed delayed or reduced brachial artery flow mediated dilatation (FMD) reactivity and higher carotid femoral pulse wave velocity (PWV), as compared to healthy controls [53,54,59,68,78,91–96]. On the other hand, Bradley et al. demonstrated that carotid-radial PWV, but not carotid-femoral PWV, is higher in adolescents with T1D than in healthy controls [93]. In young patients with T1D, arterial stiffness is positively associated with glycated hemoglobin levels, disease duration and insulin resistance [97]. When it comes to carotid intima-media thickness (cIMT), an early marker of atherosclerosis, the SEARCH CVD study by analyzing data from 298 adolescents with diabetes, showed that BMI is a strong predictor of cIMT over time [45], and that cIMT increases in young patients with the worst glycometabolic control [98,99]. The mean cIMT correlates positively with hypertension, retinopathy, microalbuminuria, and in males with HDL cholesterol too [100].

7. Early Treatment of Children and Adolescents with Diabetes

In pediatric patients with diabetes, CV risk begins early and grows over time, and thus maintaining an optimal glycometabolic control in the long term is mandatory [101,102]. In the management of children and adolescents with diabetes, a pivotal role is played by health education [101]. The identification of a nutritional educational plan, with the aim of managing the intake of nutrients is essential [101]. Regular physical activity improves glycemic control, insulin sensitivity, lipid profile, body composition, wellbeing and cardiovascular health [103]. Therapeutic strategies used in the treatment of young patients with T1D and T2D partially differ from those used in adults [101]. Indeed, insulin therapy is recommended in children and adolescents with T1D, while metformin, insulin and liraglutide are approved for clinical use in children and adolescents with T2D [101]. Intensive insulin therapy allows one to achieve glycemic control, while it can facilitate weight gain, central adiposity, rises in blood pressure, and a more atherogenic lipoprotein profile [104,105]. In young patients with T2D, a more aggressive treatment with metformin and rosiglitazone results in a better durability, with beneficial consequences also on the development of micro- and macro- complications [106,107]. Recently, a secondary analysis of the same population demonstrated that metformin ameliorates lipoprotein profile, glycemic control, blood pressure and BMI, suggesting the role of metformin in improving CV parameters [108]. Data from a pediatric diabetes consortium registry analyzing young patients with T2D demonstrated the durability of metformin monotherapy in those with lower HbA1c

and a more recent onset of the disease [109]. A growing number of studies showed that metformin enhances insulin sensitivity and reduces insulin dose in youth with T1D, but also improves vascular markers [105,110].

The sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are two classes of anti-diabetic drugs that have demonstrated to exert cardioprotective effects in multiple cardiovascular and renal outcomes trials in adults with T2D, on primary and secondary prevention [111–114]. Moreover, their effectiveness and safety are also being tested in the treatment of patients with T1D [115–117]. Recently, Tamborlane et al. demonstrated the efficacy of liraglutide in children and adolescents with diabetes aged between 10 to 17, but they also observed an increased number of gastrointestinal adverse effects [118].

In line with these observations, novel antidiabetic therapies should be tested as a treatment of young patients, either with T1D or T2D, with the aim not only of optimizing glycemic control, but also of mitigating their CV risk (Table 4). Further studies are needed to evaluate SGLT2i and GLP1RA efficacy and safety in large cohorts of young patients with diabetes. Current guidelines recommend the use of drugs to control hypertension and dyslipidemia after changes in lifestyle in children and adolescents with diabetes [102,119]. However, there is concern about the use of statins and antihypertensive drugs in this population, for the lack of large intervention trials in the young and their teratogenic effect. More recently, regenerative therapy has proven to be a useful and innovative strategy in preventing and treating vascular complications in diabetes. Even further clinical trials are required; these therapies might be of particular interest in the young, who have a higher cellular regenerative capacity than adults [51,120].

Table 2. Studies Evaluating Cardiovascular Biomarkers in Children and Adolescents with Diabetes.

Author	Publication Year	Sample		Age		HbA1c		DM Duration	Peripheral Biomarkers
		DM	HC	DM	HC	DM	HC		
Glowinska [69]	2005	51	27	15.5 ± 3.8	15.2 ± 2.1	NA	NA	NA	↑ sICAM-1, sVCAM, sE-selectin
Schwab [52]	2007	94	40	12.3 (8.5–16.8)	12.3 (7.5–15.2)	7.7 (6.8–10.0)	4.8 (1.2–5-5)	3.8 (1.8–9.8)	↑ hs-CRP, L-selectin, sICAM, vWF, PAP, PAI
Zorena [56]	2013	53	32	12.5 ± 2.9	13.8 ± 3.3	7.6 ± 1.1	3.2 ± 0.8	4.3 ± 2.5	↑ AGEs, TNF-α, VEGF, IL-12
El Samahy [121]	2013	50	50	9.7 ± 3.4	9.8 ± 3.1	NA	NA	4.5 ± 3.5	↑NO
Machnica [55]	2014	52	20	14.0 ± 3.0	13.0 ± 3.0	7.1 ± 0.9	NA	5.0 ± 1.9	↑ sVCAM, TNF-α, IL-6
Eltayeb [53]	2014	30	30	11.1 ± 3.8	9.8 ± 3.5	9.7 ± 2.2	4.9 ± 0.4	3.9 ± 0.6	↑ hsCRP, CECs ↓ vitamin C
Aburawi 1 [70]	2016	79	47	18.6 ± 4.8	17.5 ± 4.6	9.4 ± 2.1	NA	6.8 ± 4.1	↑ sICAM-1, sVCAM
Aburawi 2 [70]	2016	55	47	23.3 ± 5.8	17.5 ± 4.6	7.8 ± 2.5	NA	4.3 ± 3.1	↑ sICAM-1, sVCAM
El-Asrar 1 [122]	2016	21	30	11.5 ± 3.1	10.7 ± 3.2	7.4 ± 0.9	NA	8.0 ± 1.6	↑Angiopoietin-2
El-Asrar 2 [122]	2016	39	30	11.4 ± 3.7	10.7 ± 3.2	9.1 ± 1.3	NA	8.3 ± 1.8	↑Angiopoietin-2
Sochett [123]	2017	51	59	14.8 (10.9–16.8)	13.9 (10.0–17.0)	9.0 ± 1.0	5.0 ± 0.0	6.7 (2.0–16.8)	↑ EGF, PDGF-BB, sCD40L, PDGF-AA, GRO
Rostampour [124]	2017	29	29	11.7 ± 1.9	10.7 ± 2.0	NA	NA	NA	↑ sICAM-1
Fathollahi [71]	2018	48	39	24.2 ± 8.2	28.5 ± 7.2	NA	NA	NA	↑ sICAM-1 = sVCAM ↓ sE-selectin
Karavanaki [125]	2018	56	28	12.0 ± 2.7	12.1 ± 3.3	8.0 ± 1.5	4.1 ± 0.9	5.4 ± 2.8	= OPG, RANKL
Zhang [54]	2019	175	150	12.1 ± 2.5	12.2 ± 1.97	7.8 ± 1.3	4.9 ± 1.6	4.7 ± 2.4	↑ TNF-α, IL-4, hs-CRP, leptin

Data are presented as mean ± SD or median (range). Abbreviations: DM, diabetes mellitus; HC, health control; NA, not available; sICAM-1, serum intercellular adhesion molecule-1; sVCAM-1, serum vascular cell adhesion molecule-1; sE-selectin, serum E-selectin; hs-CRP, high sensitivity-C reactive protein; vWF, von Willebrand factor antigen; PAP, plasmin/ α 2-antiplasmin complex; PAI, plasminogen activator inhibitor; AGEs, advanced glycation end-products; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor; IL-12, interleukin-12; NO, nitric oxide; CECs, circulating endothelial cells; EGF, endothelial growth factor; PDGF-BB, platelet-derived growth factor-BB; sCD40L, soluble cluster of differentiation 40 ligand; PDGF-AA, platelet-derived growth factor-AA; GRO, growth regulated oncogene; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor kappa ligand.

Table 3. Studies Evaluating Non-invasive Vascular Test in Children and Adolescents with Diabetes.

Author	Publication Year	Sample		Age		HbA1c		DM Duration	Non-Invasive Vascular Test
		DM	HC	DM	HC	DM	HC		
Urbina [126]	2013	402	206	18.8 ± 3.3	19.2 ± 3.3	8.9 ± 1.8	5.0 ± 0.3	9.8 ± 3.8	↑ bulb cIMT = cIMT, PWV
El Samahy [121]	2013	50	50	9.7 ± 3.4	9.8 ± 3.1	NA	NA	4.5 ± 3.5	↑ cIMT
Eltayeb [53]	2014	30	30	11.1 ± 3.8	9.8 ± 3.5	9.7 ± 2.2	4.9 ± 0.4	3.9 ± 0.6	↑ cIMT ↓ FMD
Ciftel [78]	2014	42	40	13.2 ± 2.6	13.0 ± 2.8	9.0 ± 1.4	NA	6.9 ± 1.7	↑ cIMT ↓ FMD
Pezeshki Rad [127]	2014	40	40	10.6 ± 4.1	10.5 ± 3.2	9.4 ± 2.7	NA	4.2 ± 3.0	↑ cIMT
Atabek [128]	2014	159	100	12.3 ± 4.2	12.2 ± 4.5	9.7 ± 2.5	5.3 ± 1.8	3.8 ± 2.5	↑ cIMT
Shah [40]	2015	402	206	18.8 ± 3.3	19.2 ± 3.3	8.9 ± 1.8	5.0 ± 0.3	9.8 ± 3.8	↑ PWV
Bradley [93]	2016	199	178	14.4 ± 1.6	14.4 ± 2.1	8.5 ± 1.2	5.4 ± 0.2	7.2 ± 3.1	↑ = PWV
El-Asrar 1 [122]	2016	21	30	11.5 ± 3.1	10.7 ± 3.2	7.4 ± 0.9	NA	8.0 ± 1.6	↑ cIMT, aIMT
El-Asrar 2 [122]	2016	39	30	11.4 ± 3.7	10.7 ± 3.2	9.1 ± 1.3	NA	8.3 ± 1.8	↑ cIMT, aIMT
Terlemez [129]	2016	72	77	12.8 ± 3.7	12.3 ± 1.6	8.6 ± 1.9	NA	3.9 ± 2.6	↑ PWV
Nascimento [94]	2017	22	58	8.6 ± 1.7	8.3 ± 1.8	8.8 ± 1.5	5.3 ± 0.2	> 5	= FMD, cIMT
Nascimento [94]	2017	9	58	10.1 ± 1.2	8.3 ± 1.8	9.5 ± 1.7	5.3 ± 0.2	< 5	↓FMD = cIMT
Rostampour [124]	2017	29	29	11.7 ± 1.9	10.7 ± 2.0	NA	NA	NA	↑ cIMT
Pillay [95]	2018	38	28	13.0 ± 2.9	13.9 ± 2.7	8.8(6.6–14)	5.2(4.7–5.7)	5.4 ± 4.6	↓ FMD
Lilje [130]	2018	38	38	13.4 ± 3.4	5.8 ± 4.3	9.7 ± 1.6	NA	5.8 ± 4.3	↑aIMT, fIMT = cIMT
Karavanaki [125]	2018	56	28	12.0 ± 2.7	12.1 ± 3.3	8.0 ± 1.5	4.1 ± 0.9	5.4 ± 2.8	= cIMT
Zhang [54]	2019	175	150	12.1 ± 2.5	12.2 ± 1.9	7.8 ± 1.3	4.9 ± 1.6	4.7 ± 2.4	↑ cIMT, aIMT ↓ FMD
Podgorski [131]	2019	50	50	13.4 ± 3.8	13.1 ± 4.1	7.6 ± 1.2	NA	6.5 ± 3.8	↑ PWV = cIMT
Glackin [132]	2020	57	29	13.9 ± 2.3	15.1 ± 2.2	7.8 ± 1.8	5.3 ± 0.3	5.4 ± 4.1	= cIMT

Data are presented as mean ± SD or median (range). Abbreviations: DM, diabetes mellitus; HC, health control; NA, not available; cIMT, carotid intima media thickness; PWV, pulse wave velocity; FMD, flow mediated dilatation; aIMT, aortic intima media thickness; fIMT, femoral intima media thickness.

Table 4. Effects of Hypoglycemic Therapies on Different Outcomes in Children and Adolescents with Diabetes.

Hypoglycemic Therapy	Diabetes Control	Insulin Sensitivity	Blood Pressure	Atherogenic Profile	CV Health	Body Weight
Education	↑	NA	NA	NA	↑	NA
Diet	↑	⟷	NA	↓	⟷	↓
Physical activity	↑	↑	⟷	↓	↑	↓
Insulin	↑	⟷	↑	↑	⟷	↑
Metformin	↑	↑	⟷	⟷	↑	⟷/↓
GLP1RA	↑	NA	⟷	⟷	NA	↓

Abbreviations: CV, cardiovascular; NA, not available.

8. Conclusions

CV disease still remains the leading cause of mortality in diabetes, and the onset of diabetes in pediatric age results in an increased risk for lifelong CV disease. The prevention, or at least the delay, of diabetic complications still represents a challenge for clinicians and caregivers of pediatric patients. If targeted early, cardiovascular complications may be potentially reversible, so interventions should be initiated as soon as possible to avoid the establishment of potentially untreatable CV disease. The CV risk in children and adolescents not only results from the deleterious effects of hyperglycemia, but also can be mediated by others CV risk factors, such as dyslipidemia, hypertension, albuminuria, overweight or obesity. Efforts are needed to better understand the pathophysiology of CV risk in children and adolescents with T1D and T2D, to avoid CV diseases in patients with diabetes.

Conflicts of Interest: The authors declare no conflict of interest. This study was performed without the support or involvement of any external funding source or study sponsor in any phase of the investigation, or in the writing or submission of the manuscript.

Abbreviations

CV	Cardiovascular
T1D	Type 1 diabetes
T2D	Type 2 diabetes
FMD	Flow mediated dilatation
cIMT	Carotid intima-media thickness
PWV	Pulse wave velocity
AGEs	Advanced glycation end-products
BMI	Body mass index

References

1. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res. Clin. Pract.* **2019**, *157*, 107843. [CrossRef] [PubMed]

2. Williams, R.; Karuranga, S.; Malanda, B.; Saeedi, P.; Basit, A.; Besancon, S.; Bommer, C.; Esteghamati, A.; Ogurtsova, K.; Zhang, P.; et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res. Clin. Pract.* **2020**, *162*, 108072. [CrossRef]

3. Pettitt, D.J.; Talton, J.; Dabelea, D.; Divers, J.; Imperatore, G.; Lawrence, J.M.; Liese, A.D.; Linder, B.; Mayer-Davis, E.J.; Pihoker, C.; et al. Prevalence of diabetes in U.S. youth in 2009: The SEARCH for diabetes in youth study. *Diabetes Care* **2014**, *37*, 402–408. [CrossRef] [PubMed]

4. Jensen, E.T.; Dabelea, D. Type 2 Diabetes in Youth: New Lessons from the SEARCH Study. *Curr. Diab. Rep.* **2018**, *18*, 36. [CrossRef] [PubMed]

5. Breyer, M.K.; Ofenheimer, A.; Altziebler, J.; Hartl, S.; Burghuber, O.C.; Studnicka, M.; Purin, D.; Heinzle, C.; Drexel, H.; Franssen, F.M.E.; et al. Marked differences in prediabetes- and diabetes-associated comorbidities between men and women-Epidemiological results from a general population-based cohort aged 6–80 years-The LEAD (Lung, hEart, sociAl, boDy) study. *Eur. J. Clin. Investig.* **2020**, *50*, e13207. [CrossRef] [PubMed]

6. Lobstein, T.; Jackson-Leach, R. Planning for the worst: Estimates of obesity and comorbidities in school-age children in 2025. *Pediatr. Obes.* **2016**, *11*, 321–325. [CrossRef]

7. Xu, Z.R.; Zhang, M.Y.; Ni, J.W.; Cheng, R.Q.; Zheng, Z.Q.; Xi, L.; Luo, F.H. Clinical characteristics and beta-cell function of Chinese children and adolescents with type 2 diabetes from 2009 to 2018. *World J. Pediatr.* **2019**, *15*, 405–411. [CrossRef]

8.　　Jones, S.; Khanolkar, A.R.; Gevers, E.; Stephenson, T.; Amin, R. Cardiovascular risk factors from diagnosis in children with type 1 diabetes mellitus: A longitudinal cohort study. *BMJ Open Diabetes Res. Care* **2019**, *7*, e000625. [CrossRef]

9.　　Maffeis, C.; Birkebaek, N.H.; Konstantinova, M.; Schwandt, A.; Vazeou, A.; Casteels, K.; Jali, S.; Limbert, C.; Pundziute-Lycka, A.; Toth-Heyn, P.; et al. Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: Data from the international SWEET registry. *Pediatr. Diabetes* **2018**, *19*, 1211–1220. [CrossRef]

10.　Ferrara-Cook, C.; Geyer, S.M.; Evans-Molina, C.; Libman, I.M.; Becker, D.J.; Gitelman, S.E.; Redondo, M.J.; Type 1 Diabetes TrialNet Study Group. Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. *Diabetes Care* **2020**, *43*, 580–587. [CrossRef] [PubMed]

11.　Bacha, F.; Gungor, N.; Lee, S.; Arslanian, S.A. Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. *Pediatr. Diabetes* **2013**, *14*, 106–111. [CrossRef] [PubMed]

12.　Klingensmith, G.J.; Pyle, L.; Arslanian, S.; Copeland, K.C.; Cuttler, L.; Kaufman, F.; Laffel, L.; Marcovina, S.; Tollefsen, S.E.; Weinstock, R.S.; et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: Results from the TODAY study. *Diabetes Care* **2010**, *33*, 1970–1975. [CrossRef] [PubMed]

13.　Elder, D.A.; Hornung, L.N.; Khoury, J.C.; D'Alessio, D.A. beta-Cell Function Over Time in Adolescents With New Type 2 Diabetes and Obese Adolescents Without Diabetes. *J. Adolesc. Health* **2017**, *61*, 703–708. [CrossRef] [PubMed]

14.　Dabelea, D.; Mayer-Davis, E.J.; Andrews, J.S.; Dolan, L.M.; Pihoker, C.; Hamman, R.F.; Greenbaum, C.; Marcovina, S.; Fujimoto, W.; Linder, B.; et al. Clinical evolution of beta cell function in youth with diabetes: The SEARCH for Diabetes in Youth study. *Diabetologia* **2012**, *55*, 3359–3368. [CrossRef] [PubMed]

15.　Steinarsson, A.O.; Rawshani, A.; Gudbjornsdottir, S.; Franzen, S.; Svensson, A.M.; Sattar, N. Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: A longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register. *Diabetologia* **2018**, *61*, 599–606. [CrossRef] [PubMed]

16.　Tanrikulu, M.A.; Agirbasli, M.; Berenson, G. Primordial Prevention of Cardiometabolic Risk in Childhood. *Adv. Exp. Med. Biol.* **2017**, *956*, 489–496.

17.　Sarwar, N.; Gao, P.; Seshasai, S.R.; Gobin, R.; Kaptoge, S.; Di Angelantonio, E.; Ingelsson, E.; Lawlor, D.A.; Selvin, E.; Emerging Risk Factors Collaboration; et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. *Lancet* **2010**, *375*, 2215–2222.

18.　Rawshani, A.; Sattar, N.; Franzen, S.; Rawshani, A.; Hattersley, A.T.; Svensson, A.M.; Eliasson, B.; Gudbjornsdottir, S. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: A nationwide, register-based cohort study. *Lancet* **2018**, *392*, 477–486. [CrossRef]

19.　Svane, J.; Lynge, T.H.; Pedersen-Bjergaard, U.; Jespersen, T.; Gislason, G.H.; Risgaard, B.; Winkel, B.G.; Tfelt-Hansen, J. Cause-specific mortality in children and young adults with diabetes mellitus: A Danish nationwide cohort study. *Eur. J. Prev. Cardiol.* **2019**, in press. [CrossRef]

20.　Lindberg, L.; Danielsson, P.; Persson, M.; Marcus, C.; Hagman, E. Association of childhood obesity with risk of early all-cause and cause-specific mortality: A Swedish prospective cohort study. *PLoS Med.* **2020**, *17*, e1003078. [CrossRef]

21.　Constantino, M.I.; Molyneaux, L.; Limacher-Gisler, F.; Al-Saeed, A.; Luo, C.; Wu, T.; Twigg, S.M.; Yue, D.K.; Wong, J. Long-term complications and mortality in young-onset diabetes: Type 2 diabetes is more hazardous and lethal than type 1 diabetes. *Diabetes Care* **2013**, *36*, 3863–3869. [CrossRef] [PubMed]

22.　Reynolds, K.; Saydah, S.H.; Isom, S.; Divers, J.; Lawrence, J.M.; Dabelea, D.; Mayer-Davis, E.J.; Imperatore, G.; Bell, R.A.; Hamman, R.F. Mortality in youth-onset type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth study. *J. Diabetes Complicat.* **2018**, *32*, 545–549. [CrossRef] [PubMed]

23.　Rodriguez, B.L.; Fujimoto, W.Y.; Mayer-Davis, E.J.; Imperatore, G.; Williams, D.E.; Bell, R.A.; Wadwa, R.P.; Palla, S.L.; Liu, L.L.; Kershnar, A.; et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: The SEARCH for diabetes in youth study. *Diabetes Care* **2006**, *29*, 1891–1896. [CrossRef] [PubMed]

24. Kim, G.; Divers, J.; Fino, N.F.; Dabelea, D.; Lawrence, J.M.; Reynolds, K.; Bell, R.A.; Mayer-Davis, E.; Crume, T.; Pettitt, D.J.; et al. Trends in prevalence of cardiovascular risk factors from 2002 to 2012 among youth early in the course of type 1 and type 2 diabetes. The SEARCH for Diabetes in Youth Study. *Pediatr. Diabetes* **2019**, *20*, 693–701. [CrossRef]

25. Dabelea, D.; Stafford, J.M.; Mayer-Davis, E.J.; D'Agostino, R., Jr.; Dolan, L.; Imperatore, G.; Linder, B.; Lawrence, J.M.; Marcovina, S.M.; Mottl, A.K.; et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. *JAMA* **2017**, *317*, 825–835. [CrossRef]

26. Jie, K.E.; Goossens, M.H.; van Oostrom, O.; Lilien, M.R.; Verhaar, M.C. Circulating endothelial progenitor cell levels are higher during childhood than in adult life. *Atherosclerosis* **2009**, *202*, 345–347. [CrossRef]

27. Miller, R.G.; Costacou, T.; Orchard, T.J. Risk Factor Modeling for Cardiovascular Disease in Type 1 Diabetes in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study: A Comparison With the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). *Diabetes* **2019**, *68*, 409–419.

28. Peters, S.A.; Huxley, R.R.; Woodward, M. Diabetes as risk factor for incident coronary heart disease in women compared with men: A systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia* **2014**, *57*, 1542–1551. [CrossRef]

29. Peters, S.A.; Huxley, R.R.; Woodward, M. Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. *Lancet* **2014**, *383*, 1973–1980. [CrossRef]

30. Stankute, I.; Dobrovolskiene, R.; Danyte, E.; Razanskaite-Virbickiene, D.; Jasinskiene, E.; Mockeviciene, G.; Marciulionyte, D.; Schwitzgebel, V.M.; Verkauskiene, R. Factors Affecting Cardiovascular Risk in Children, Adolescents, and Young Adults with Type 1 Diabetes. *J. Diabetes Res.* **2019**, *2019*, 9134280. [CrossRef]

31. Diabetes Control and Complications Trial/Epidemiology of Diabetes I; Complications Study Research G. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. *Diabetes Care* **2016**, *39*, 686–693. [CrossRef] [PubMed]

32. Lu, J.; Ma, X.; Shen, Y.; Wu, Q.; Wang, R.; Zhang, L.; Mo, Y.; Lu, W.; Zhu, W.; Bao, Y.; et al. Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes. *Diabetes Technol. Ther.* **2020**, *22*, 72–78. [CrossRef] [PubMed]

33. Kataoka, Y.; Hosoda, K.; Makino, H.; Matsubara, M.; Matsuo, M.; Ohata, Y.; Koezuka, R.; Tamanaha, T.; Tomita, T.; Honda-Kohmo, K.; et al. The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: Rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL). *Cardiovasc. Diagn. Ther.* **2019**, *9*, 431–438. [PubMed]

34. Jamiolkowska, M.; Jamiolkowska, I.; Luczynski, W.; Tolwinska, J.; Bossowski, A.; Glowinska Olszewska, B. Impact of Real-Time Continuous Glucose Monitoring Use on Glucose Variability and Endothelial Function in Adolescents with Type 1 Diabetes: New Technolog—New Possibility to Decrease Cardiovascular Risk? *J. Diabetes Res.* **2016**, *2016*, 4385312. [CrossRef]

35. Fahrmann, E.R.; Adkins, L.; Loader, C.J.; Han, H.; Rice, K.M.; Denvir, J.; Driscoll, H.K. Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. *Diabetes Res. Clin. Pract.* **2015**, *107*, 280–289. [CrossRef]

36. Nadeau, K.J.; Regensteiner, J.G.; Bauer, T.A.; Brown, M.S.; Dorosz, J.L.; Hull, A.; Zeitler, P.; Draznin, B.; Reusch, J.E. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. *J. Clin. Endocrinol. Metab.* **2010**, *95*, 513–521. [CrossRef]

37. Khawandanah, J. Double or hybrid diabetes: A systematic review on disease prevalence, characteristics and risk factors. *Nutr. Diabetes* **2019**, *9*, 33. [CrossRef]

38. Schwab, K.O.; Doerfer, J.; Marg, W.; Schober, E.; Holl, R.W.; DPV Science Initiative; the Competence Network Diabetes mellitus. Characterization of 33,488 children and adolescents with type 1 diabetes based on the gender-specific increase of cardiovascular risk factors. *Pediatr. Diabetes* **2010**, *11*, 357–363. [CrossRef]

39. Group, T.S. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: The TODAY clinical trial. *Diabetes Care* **2013**, *36*, 1735–1741. [CrossRef]

40. Shah, A.S.; Wadwa, R.P.; Dabelea, D.; Hamman, R.F.; D'Agostino, R., Jr.; Marcovina, S.; Daniels, S.R.; Dolan, L.M.; Fino, N.F.; Urbina, E.M. Arterial stiffness in adolescents and young adults with and without type 1 diabetes: The SEARCH CVD study. *Pediatr. Diabetes* **2015**, *16*, 367–374. [CrossRef]

41. Chiesa, S.T.; Charakida, M.; McLoughlin, E.; Nguyen, H.C.; Georgiopoulos, G.; Motran, L.; Elia, Y.; Marcovecchio, M.L.; Dunger, D.B.; Dalton, R.N.; et al. Elevated high-density lipoprotein in adolescents with Type 1 diabetes is associated with endothelial dysfunction in the presence of systemic inflammation. *Eur. Heart J.* **2019**, *40*, 3559–3566. [CrossRef]

42. Flokas, M.E.; Zeymo, A.; Mete, M.; Anhalt, H.; Rother, K.I.; Gourgari, E. Overweight and obese children with optimal control in the T1D Exchange Registry: How are they different from lean children with optimal control? *J. Diabetes Complicat.* **2020**, *34*, 107513. [CrossRef] [PubMed]

43. Prado, M.M.; Carrizo, T.; Abregu, A.V.; Merono, T. Non-HDL-cholesterol and C-reactive protein in children and adolescents with type 1 diabetes. *J. Pediatr. Endocrinol. Metab.* **2017**, *30*, 285–288. [CrossRef] [PubMed]

44. Cree-Green, M.; Maahs, D.M.; Ferland, A.; Hokanson, J.E.; Wang, H.; Pyle, L.; Kinney, G.L.; King, M.; Eckel, R.H.; Nadeau, K.J. Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes. *Pediatr. Diabetes* **2016**, *17*, 257–265. [CrossRef] [PubMed]

45. Shah, A.S.; Dabelea, D.; Fino, N.F.; Dolan, L.M.; Wadwa, R.P.; D'Agostino, R., Jr.; Hamman, R.; Marcovina, S.; Daniels, S.R.; Urbina, E.M. Predictors of Increased Carotid Intima-Media Thickness in Youth with Type 1 Diabetes: The SEARCH CVD Study. *Diabetes Care* **2016**, *39*, 418–425. [CrossRef]

46. Furman, D.; Campisi, J.; Verdin, E.; Carrera-Bastos, P.; Targ, S.; Franceschi, C.; Ferrucci, L.; Gilroy, D.W.; Fasano, A.; Miller, G.W.; et al. Chronic inflammation in the etiology of disease across the life span. *Nat. Med.* **2019**, *25*, 1822–1832. [CrossRef]

47. Marcovecchio, M.L.; de Giorgis, T.; Di Giovanni, I.; Chiavaroli, V.; Chiarelli, F.; Mohn, A. Association between markers of endothelial dysfunction and early signs of renal dysfunction in pediatric obesity and type 1 diabetes. *Pediatr. Diabetes* **2017**, *18*, 283–289. [CrossRef]

48. Odermarsky, M.; Pesonen, E.; Sorsa, T.; Lernmark, A.; Pussinen, P.J.; Liuba, P. HLA, infections and inflammation in early stages of atherosclerosis in children with type 1 diabetes. *Acta Diabetol.* **2018**, *55*, 41–47. [CrossRef]

49. Heier, M.; Margeirsdottir, H.D.; Brunborg, C.; Hanssen, K.F.; Dahl-Jorgensen, K.; Seljeflot, I. Inflammation in childhood type 1 diabetes; influence of glycemic control. *Atherosclerosis* **2015**, *238*, 33–37. [CrossRef]

50. Group, T.S. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: The TODAY clinical trial. *Diabetes Care* **2013**, *36*, 1758–1764. [CrossRef]

51. Petrelli, A.; Di Fenza, R.; Carvello, M.; Gatti, F.; Secchi, A.; Fiorina, P. Strategies to reverse endothelial progenitor cell dysfunction in diabetes. *Exp. Diabetes Res.* **2012**, *2012*, 471823. [CrossRef] [PubMed]

52. Schwab, K.O.; Doerfer, J.; Krebs, A.; Krebs, K.; Schorb, E.; Hallermann, K.; Superti-Furga, A.; Zieger, B.; Marz, W.; Schmidt-Trucksass, A.; et al. Early atherosclerosis in childhood type 1 diabetes: Role of raised systolic blood pressure in the absence of dyslipidaemia. *Eur. J. Pediatr.* **2007**, *166*, 541–548. [CrossRef] [PubMed]

53. Eltayeb, A.A.; Ahmad, F.A.; Sayed, D.M.; Osama, A.M. Subclinical vascular endothelial dysfunctions and myocardial changes with type 1 diabetes mellitus in children and adolescents. *Pediatr. Cardiol.* **2014**, *35*, 965–974. [CrossRef] [PubMed]

54. Zhang, Y.; Zhang, H.; Li, P. Cardiovascular risk factors in children with type 1 diabetes mellitus. *J. Pediatr. Endocrinol. Metab.* **2019**, *32*, 699–705. [CrossRef] [PubMed]

55. Machnica, L.; Deja, G.; Polanska, J.; Czupryniak, L.; Szymanska-Garbacz, E.; Loba, J.; Jarosz-Chobot, P. Blood pressure disturbances and endothelial dysfunction markers in children and adolescents with type 1 diabetes. *Atherosclerosis* **2014**, *237*, 129–134. [CrossRef] [PubMed]

56. Zorena, K.; Kula, M.; Malinowska, E.; Raczynska, D.; Mysliwiec, M.; Raczynska, K. Threshold serum concentrations of tumour necrosis factor alpha (TNFalpha) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM). *Hum. Immunol.* **2013**, *74*, 75–81. [CrossRef]

57. Morales, A.; Wasserfall, C.; Brusko, T.; Carter, C.; Schatz, D.; Silverstein, J.; Ellis, T.; Atkinson, M. Adiponectin and leptin concentrations may aid in discriminating disease forms in children and adolescents with type 1 and type 2 diabetes. *Diabetes Care* **2004**, *27*, 2010–2014. [CrossRef]

58. Snell-Bergeon, J.K.; West, N.A.; Mayer-Davis, E.J.; Liese, A.D.; Marcovina, S.M.; D'Agostino, R.B., Jr.; Hamman, R.F.; Dabelea, D. Inflammatory markers are increased in youth with type 1 diabetes: The SEARCH Case-Control study. *J. Clin. Endocrinol. Metab.* **2010**, *95*, 2868–2876. [CrossRef]

59. Alman, A.C.; Talton, J.W.; Wadwa, R.P.; Urbina, E.M.; Dolan, L.M.; Hamman, R.F.; D'Agostino, R.B., Jr.; Marcovina, S.M.; Dabelea, D.M. Inflammation, adiposity, and progression of arterial stiffness in adolescents with type 1 diabetes: The SEARCH CVD Study. *J. Diabetes Complicat.* **2018**, *32*, 995–999. [CrossRef]

60. Balagopal, P.; George, D.; Patton, N.; Yarandi, H.; Roberts, W.L.; Bayne, E.; Gidding, S. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: A randomized controlled study in adolescents. *J. Pediatr.* **2005**, *146*, 342–348. [CrossRef]

61. Liese, A.D.; Ma, X.; Ma, X.; Mittleman, M.A.; The, N.S.; Standiford, D.A.; Lawrence, J.M.; Pihoker, C.; Marcovina, S.M.; Mayer-Davis, E.J.; et al. Dietary quality and markers of inflammation: No association in youth with type 1 diabetes. *J. Diabetes Complicat.* **2018**, *32*, 179–184. [CrossRef] [PubMed]

62. Brar, P.C.; Kohn, B. Use of the microbiome in the management of children with type 2 diabetes mellitus. *Curr. Opin. Pediatr.* **2019**, *31*, 524–530. [CrossRef] [PubMed]

63. Wang, P.; Xu, Y.Y.; Lv, T.T.; Guan, S.Y.; Li, X.M.; Li, X.P.; Pan, H.F. Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Angiology* **2019**, *70*, 141–159. [CrossRef] [PubMed]

64. Lanfredini, M.; Fiorina, P.; Peca, M.G.; Veronelli, A.; Mello, A.; Astorri, E.; Dall'Aglio, P.; Craveri, A. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. *Metabolism* **1998**, *47*, 915–921. [CrossRef]

65. Jarvisalo, M.J.; Raitakari, M.; Toikka, J.O.; Putto-Laurila, A.; Rontu, R.; Laine, S.; Lehtimaki, T.; Ronnemaa, T.; Viikari, J.; Raitakari, O.T. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. *Circulation* **2004**, *109*, 1750–1755. [CrossRef]

66. King, G.L.; Loeken, M.R. Hyperglycemia-induced oxidative stress in diabetic complications. *Histochem. Cell Biol.* **2004**, *122*, 333–338. [CrossRef]

67. Folli, F.; Guzzi, V.; Perego, L.; Coletta, D.K.; Finzi, G.; Placidi, C.; La Rosa, S.; Capella, C.; Socci, C.; Lauro, D.; et al. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. *PLoS ONE* **2010**, *5*, e9923. [CrossRef]

68. Babar, G.S.; Zidan, H.; Widlansky, M.E.; Das, E.; Hoffmann, R.G.; Daoud, M.; Alemzadeh, R. Impaired endothelial function in preadolescent children with type 1 diabetes. *Diabetes Care* **2011**, *34*, 681–685. [CrossRef]

69. Glowinska, B.; Urban, M.; Peczynska, J.; Florys, B. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. *Metabolism* **2005**, *54*, 1020–1026. [CrossRef]

70. Aburawi, E.H.; AlKaabi, J.; Zoubeidi, T.; Shehab, A.; Lessan, N.; Al Essa, A.; Yasin, J.; Saadi, H.; Souid, A.K. Subclinical Inflammation and Endothelial Dysfunction in Young Patients with Diabetes: A Study from United Arab Emirates. *PLoS ONE* **2016**, *11*, e0159808. [CrossRef] [PubMed]

71. Fathollahi, A.; Massoud, A.; Amirzargar, A.A.; Aghili, B.; Nasli Esfahani, E.; Rezaei, N. sICAM-1, sVCAM-1 and sE-Selectin Levels in Type 1 Diabetes. *Fetal. Pediatr. Pathol.* **2018**, *37*, 69–73. [CrossRef]

72. Babar, G.; Clements, M.; Dai, H.; Raghuveer, G. Assessment of biomarkers of inflammation and premature atherosclerosis in adolescents with type-1 diabetes mellitus. *J. Pediatr. Endocrinol. Metab.* **2019**, *32*, 109–113. [CrossRef]

73. Gidding, S.S.; Bacha, F.; Bjornstad, P.; Levitt Katz, L.E.; Levitsky, L.L.; Lynch, J.; Tryggestad, J.B.; Weinstock, R.S.; El Ghormli, L.; Lima, J.A.C.; et al. Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. *J. Pediatr.* **2018**, *192*, 86–92 e5. [CrossRef]

74. Mameli, C.; Mazzantini, S.; Ben Nasr, M.; Fiorina, P.; Scaramuzza, A.E.; Zuccotti, G.V. Explaining the increased mortality in type 1 diabetes. *World J. Diabetes* **2015**, *6*, 889–895. [CrossRef]

75. Aneja, A.; Tang, W.H.; Bansilal, S.; Garcia, M.J.; Farkouh, M.E. Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges, and therapeutic options. *Am. J. Med.* **2008**, *121*, 748–757. [CrossRef] [PubMed]

76. Van Heerebeek, L.; Hamdani, N.; Handoko, M.L.; Falcao-Pires, I.; Musters, R.J.; Kupreishvili, K.; Ijsselmuiden, A.J.; Schalkwijk, C.G.; Bronzwaer, J.G.; Diamant, M.; et al. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. *Circulation* **2008**, *117*, 43–51. [CrossRef] [PubMed]

77. Fiorina, P.; La Rocca, E.; Astorri, E.; Lucignani, G.; Rossetti, C.; Fazio, F.; Giudici, D.; di Carlo, V.; Cristallo, M.; Pozza, G.; et al. Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. *Diabetes Care* **2000**, *23*, 1804–1810. [CrossRef]

78. Ciftel, M.; Ertug, H.; Parlak, M.; Akcurin, G.; Kardelen, F. Investigation of endothelial dysfunction and arterial stiffness in children with type 1 diabetes mellitus and the association with diastolic dysfunction. *Diabetes Vasc. Dis. Res.* **2014**, *11*, 19–25. [CrossRef]

79. Astorri, E.; Fiorina, P.; Contini, G.A.; Albertini, D.; Magnati, G.; Astorri, A.; Lanfredini, M. Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patients. *Clin. Cardiol.* **1997**, *20*, 536–540. [CrossRef] [PubMed]

80. Ozdemir, O.; Koksoy, A.Y.; Bulus, A.D.; Andiran, N.; Yagli, E. The effects of type 1 diabetes mellitus on cardiac functions in children: Evaluation by conventional and tissue Doppler echocardiography. *J. Pediatr. Endocrinol. Metab.* **2016**, *29*, 1389–1395. [CrossRef] [PubMed]

81. Yoldas, T.; Orun, U.A.; Sagsak, E.; Aycan, Z.; Kaya, O.; Ozgur, S.; Karademir, S. Subclinical left ventricular systolic and diastolic dysfunction in type 1 diabetic children and adolescents with good metabolic control. *Echocardiography* **2018**, *35*, 227–233. [CrossRef] [PubMed]

82. Shah, A.S.; Khoury, P.R.; Dolan, L.M.; Ippisch, H.M.; Urbina, E.M.; Daniels, S.R.; Kimball, T.R. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. *Diabetologia* **2011**, *54*, 722–730. [CrossRef] [PubMed]

83. Adal, E.; Koyuncu, G.; Aydin, A.; Celebi, A.; Kavunoglu, G.; Cam, H. Asymptomatic cardiomyopathy in children and adolescents with type 1 diabetes mellitus: Association of echocardiographic indicators with duration of diabetes mellitus and metabolic parameters. *J. Pediatr. Endocrinol. Metab.* **2006**, *19*, 713–726. [CrossRef] [PubMed]

84. Levitt, K.L.; Gidding, S.S.; Bacha, F.; Hirst, K.; McKay, S.; Pyle, L.; Lima, J.A.; Group, T.S. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. *Pediatr. Diabetes* **2015**, *16*, 39–47.

85. Brunvand, L.; Heier, M.; Brunborg, C.; Hanssen, K.F.; Fugelseth, D.; Stensaeth, K.H.; Dahl-Jorgensen, K.; Margeirsdottir, H.D. Advanced glycation end products in children with type 1 diabetes and early reduced diastolic heart function. *BMC Cardiovasc. Disord.* **2017**, *17*, 133. [CrossRef]

86. Kir, M.; Cetin, B.; Demir, K.; Yilmaz, N.; Kizilca, O.; Demircan, T.; Unal, N.; Bober, E.; Saylam, G.S. Can ambulatory blood pressure monitoring detect early diastolic dysfunction in children with type 1 diabetes mellitus: Correlations with B-type natriuretic peptide and tissue Doppler findings. *Pediatr. Diabetes* **2016**, *17*, 21–27. [CrossRef]

87. Brunvand, L.; Fugelseth, D.; Stensaeth, K.H.; Dahl-Jorgensen, K.; Margeirsdottir, H.D. Early reduced myocardial diastolic function in children and adolescents with type 1 diabetes mellitus a population-based study. *BMC Cardiovasc. Disord.* **2016**, *16*, 103. [CrossRef]

88. Gusso, S.; Pinto, T.E.; Baldi, J.C.; Robinson, E.; Cutfield, W.S.; Hofman, P.L. Diastolic function is reduced in adolescents with type 1 diabetes in response to exercise. *Diabetes Care* **2012**, *35*, 2089–2094. [CrossRef]

89. Pinto, T.E.; Gusso, S.; Hofman, P.L.; Derraik, J.G.; Hornung, T.S.; Cutfield, W.S.; Baldi, J.C. Systolic and diastolic abnormalities reduce the cardiac response to exercise in adolescents with type 2 diabetes. *Diabetes Care* **2014**, *37*, 1439–1446. [CrossRef]

90. Gusso, S.; Pinto, T.; Baldi, J.C.; Derraik, J.G.B.; Cutfield, W.S.; Hornung, T.; Hofman, P.L. Exercise Training Improves but Does Not Normalize Left Ventricular Systolic and Diastolic Function in Adolescents with Type 1 Diabetes. *Diabetes Care* **2017**, *40*, 1264–1272. [CrossRef]

91. Wiltshire, E.J.; Gent, R.; Hirte, C.; Pena, A.; Thomas, D.W.; Couper, J.J. Endothelial dysfunction relates to folate status in children and adolescents with type 1 diabetes. *Diabetes* **2002**, *51*, 2282–2286. [CrossRef] [PubMed]

92. Singh, T.P.; Groehn, H.; Kazmers, A. Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus. *J. Am. Coll. Cardiol.* **2003**, *41*, 661–665. [CrossRef]

93. Bradley, T.J.; Slorach, C.; Mahmud, F.H.; Dunger, D.B.; Deanfield, J.; Deda, L.; Elia, Y.; Har, R.L.; Hui, W.; Moineddin, R.; et al. Early changes in cardiovascular structure and function in adolescents with type 1 diabetes. *Cardiovasc. Diabetol.* **2016**, *15*, 31. [CrossRef] [PubMed]

94. Nascimento, A.; Sequeira, I.J.; Vasconcelos, D.F.; Gandolfi, L.; Pratesi, R.; Nobrega, Y.K.M. Endothelial dysfunction in children with type 1 diabetes mellitus. *Arch. Endocrinol. Metab.* **2017**, *61*, 476–483. [CrossRef]

95. Pillay, S.; Anderson, J.; Couper, J.; Maftei, O.; Gent, R.; Pena, A.S. Children With Type 1 Diabetes Have Delayed Flow-Mediated Dilation. *Can. J. Diabetes* **2018**, *42*, 276–280. [CrossRef]

96. Bruzzi, P.; Predieri, B.; Patianna, V.D.; Salvini, A.; Rossi, R.; Modena, M.G.; Iughetti, L. Longitudinal evaluation of endothelial function in children and adolescents with type 1 diabetes mellitus: A long-term follow-up study. *Pediatr. Int.* **2014**, *56*, 188–195. [CrossRef]

97. Urbina, E.M.; Isom, S.; Bell, R.A.; Bowlby, D.A.; D'Agostino, R., Jr.; Daniels, S.R.; Dolan, L.M.; Imperatore, G.; Marcovina, S.M.; Merchant, A.T.; et al. Burden of Cardiovascular Risk Factors Over Time and Arterial Stiffness in Youth with Type 1 Diabetes Mellitus: The SEARCH for Diabetes in Youth Study. *J. Am. Heart Assoc.* **2019**, *8*, e010150. [CrossRef]

98. Nathan, D.M.; Lachin, J.; Cleary, P.; Orchard, T.; Brillon, D.J.; Backlund, J.Y.; O'Leary, D.H.; Genuth, S.; Diabetes, C.; Complications, T.; et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. *N. Engl. J. Med.* **2003**, *348*, 2294–2303.

99. Polak, J.F.; Backlund, J.Y.; Cleary, P.A.; Harrington, A.P.; O'Leary, D.H.; Lachin, J.M.; Nathan, D.M.; Group, D.E.R. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes* **2011**, *60*, 607–613. [CrossRef]

100. Krantz, J.S.; Mack, W.J.; Hodis, H.N.; Liu, C.R.; Liu, C.H.; Kaufman, F.R. Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. *J. Pediatr.* **2004**, *145*, 452–457. [CrossRef]

101. American Diabetes Association. 13. Children and Adolescents: Standards of Medical Care in Diabetes-2020. *Diabetes Care* **2020**, *43* (Suppl. S1), S163–S182. [CrossRef] [PubMed]

102. Donaghue, K.C.; Marcovecchio, M.L.; Wadwa, R.P.; Chew, E.Y.; Wong, T.Y.; Calliari, L.E.; Zabeen, B.; Salem, M.A.; Craig, M.E. ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents. *Pediatr. Diabetes* **2018**, *19* (Suppl. S27), 262–274. [CrossRef] [PubMed]

103. Pivovarov, J.A.; Taplin, C.E.; Riddell, M.C. Current perspectives on physical activity and exercise for youth with diabetes. *Pediatr. Diabetes* **2015**, *16*, 242–255. [CrossRef] [PubMed]

104. Biester, T.; Kordonouri, O.; Danne, T. Pharmacotherapy of type1 diabetes in children and adolescents: More than insulin? *Ther. Adv. Endocrinol. Metab.* **2018**, *9*, 157–166. [CrossRef] [PubMed]

105. Anderson, J.J.A.; Couper, J.J.; Giles, L.C.; Leggett, C.E.; Gent, R.; Coppin, B.; Pena, A.S. Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial. *J. Clin. Endocrinol. Metab.* **2017**, *102*, 4448–4456. [CrossRef] [PubMed]

106. Group, T.S.; Zeitler, P.; Hirst, K.; Pyle, L.; Linder, B.; Copeland, K.; Arslanian, S.; Cuttler, L.; Nathan, D.M.; Tollefsen, S.; et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N. Engl. J. Med.* **2012**, *366*, 2247–2256. [CrossRef] [PubMed]

107. Narasimhan, S.; Weinstock, R.S. Youth-onset type 2 diabetes mellitus: Lessons learned from the TODAY study. *Mayo Clin. Proc.* **2014**, *89*, 806–816. [CrossRef]

108. Kelsey, M.M.; Geffner, M.E.; Guandalini, C.; Pyle, L.; Tamborlane, W.V.; Zeitler, P.S.; White, N.H.; Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group. Presentation and effectiveness of early treatment of type 2 diabetes in youth: Lessons from the TODAY study. *Pediatr. Diabetes* **2016**, *17*, 212–221. [CrossRef]

109. Bacha, F.; Cheng, P.; Gal, R.L.; Kollman, C.; Tamborlane, W.V.; Klingensmith, G.J.; Manseau, K.; Wood, J.; Beck, R.W.; Pediatric Diabetes Consortium. Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry. *Horm. Res. Paediatr.* **2018**, *89*, 47–55. [CrossRef]

110. Bjornstad, P.; Schafer, M.; Truong, U.; Cree-Green, M.; Pyle, L.; Baumgartner, A.; Garcia Reyes, Y.; Maniatis, A.; Nayak, S.; Wadwa, R.P.; et al. Metformin Improves Insulin Sensitivity and Vascular Health in Youth with Type 1 Diabetes Mellitus. *Circulation* **2018**, *138*, 2895–2907. [CrossRef]

111. Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N. Engl. J. Med.* **2015**, *373*, 2117–2128. [CrossRef] [PubMed]

112. Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; Mann, J.F.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; Ravn, L.S.; et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N. Engl. J. Med.* **2016**, *375*, 311–322. [CrossRef]

113. Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N. Engl. J. Med.* **2019**, *380*, 2295–2306. [CrossRef] [PubMed]

114. Gerstein, H.C.; Colhoun, H.M.; Dagenais, G.R.; Diaz, R.; Lakshmanan, M.; Pais, P.; Probstfield, J.; Riesmeyer, J.S.; Riddle, M.C.; Ryden, L.; et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. *Lancet* **2019**, *394*, 121–130. [CrossRef]

115. Mathieu, C.; Rudofsky, G.; Phillip, M.; Araki, E.; Lind, M.; Arya, N.; Thoren, F.; Scheerer, M.F.; Iqbal, N.; Dandona, P. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. *Diabetes Obes. Metab.* **2020**, in press. [CrossRef] [PubMed]

116. Van Meijel, L.A.; Rooijackers, H.M.; Tack, C.J.; de Galan, B.E. Effect of the GLP-1 receptor agonist exenatide on impaired awareness of hypoglycemia in type 1 diabetes; a randomized controlled trial. *J. Clin. Endocrinol. Metab.* **2019**, in press. [CrossRef] [PubMed]

117. Dellepiane, S.; Ben Nasr, M.; Assi, E.; Usuelli, V.; Letizia, T.; D'Addio, F.; Zuccotti, G.V.; Fiorina, P. Sodium glucose cotransporters inhibitors in type 1 diabetes. *Pharmacol. Res.* **2018**, *133*, 1–8. [CrossRef]

118. Tamborlane, W.V.; Barrientos-Perez, M.; Fainberg, U.; Frimer-Larsen, H.; Hafez, M.; Hale, P.M.; Jalaludin, M.Y.; Kovarenko, M.; Libman, I.; Lynch, J.L.; et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. *N. Engl. J. Med.* **2019**, *381*, 637–646. [CrossRef]

119. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. *Diabetes Care* **2020**, *43* (Suppl. S1), S14–S31. [CrossRef]

120. Bassi, R.; Trevisani, A.; Tezza, S.; Ben Nasr, M.; Gatti, F.; Vergani, A.; Farina, A.; Fiorina, P. Regenerative therapies for diabetic microangiopathy. *Exp. Diabetes Res.* **2012**, *2012*, 916560. [CrossRef]

121. El Samahy, M.H.; Matter, R.M.; Youssef, O.I.; Shams El Din El Telbany, M.A.; Kamal, N.A. Relation between carotid intima media thickness and oxidative stress markers in type 1 diabetic children and adolescents. *J. Diabetes Metab. Disord.* **2013**, *12*, 50. [CrossRef] [PubMed]

122. El-Asrar, M.A.; Elbarbary, N.S.; Ismail, E.A.; Bakr, A.A. Circulating angiopoietin-2 levels in children and adolescents with type 1 diabetes mellitus: Relation to carotid and aortic intima-media thickness. *Angiogenesis* **2016**, *19*, 421–431. [CrossRef] [PubMed]

123. Sochett, E.; Noone, D.; Grattan, M.; Slorach, C.; Moineddin, R.; Elia, Y.; Mahmud, F.H.; Dunger, D.B.; Dalton, N.; Cherney, D.; et al. Relationship between serum inflammatory markers and vascular function in a cohort of adolescents with type 1 diabetes. *Cytokine* **2017**, *99*, 233–239. [CrossRef] [PubMed]

124. Rostampour, N.; Fekri, K.; Hashemi-Dehkordi, E.; Obodiat, M. Association between Vascular Endothelial Markers and Carotid Intima-Media Thickness in Children and Adolescents with Type 1 Diabetes Mellitus. *J. Clin. Diagn. Res.* **2017**, *11*, SC01–SC05. [CrossRef]

125. Karavanaki, K.; Tsouvalas, E.; Vakaki, M.; Soldatou, A.; Tsentidis, C.; Kaparos, G.; Augoulea, A.; Alexandrou, A.; Lambrinoudaki, I. Carotid intima media thickness and associations with serum osteoprotegerin and s-RANKL in children and adolescents with type 1 diabetes mellitus with increased risk for endothelial dysfunction. *J. Pediatr. Endocrinol. Metab.* **2018**, *31*, 1169–1177. [CrossRef]

126. Urbina, E.M.; Dabelea, D.; D'Agostino, R.B., Jr.; Shah, A.S.; Dolan, L.M.; Hamman, R.F.; Daniels, S.R.; Marcovina, S.; Wadwa, R.P. Effect of type 1 diabetes on carotid structure and function in adolescents and young adults: The SEARCH CVD study. *Diabetes Care* **2013**, *36*, 2597–2599. [CrossRef]

127. Pezeshki Rad, M.; Farrokh, D.; Vakili, R.; Omidbakhsh, M.; Mohammadi, M. The Association between Carotid Intima-Media Thickness and the Duration of Type 1 Diabetes in Children. *Iran. J. Pediatr.* **2014**, *24*, 249–254.

128. Atabek, M.E.; Akyurek, N.; Eklioglu, B.S.; Alp, H. Impaired systolic blood dipping and nocturnal hypertension: An independent predictor of carotid intima-media thickness in type 1 diabetic patients. *J. Diabetes Complicat.* **2014**, *28*, 51–55. [CrossRef]

129. Terlemez, S.; Bulut, Y.; Unuvar, T.; Tokgoz, Y.; Eryilmaz, U.; Celik, B. Evaluation of arterial stiffness in children with type 1 diabetes using the oscillometric method. *J. Diabetes Complicat.* **2016**, *30*, 864–867. [CrossRef]

130. Lilje, C.; Cronan, J.C.; Schwartzenburg, E.J.; Owers, E.M.; Clesi, P.; Gomez, R.; Stender, S.; Hempe, J.; Chalew, S.A.; Cardinale, J.P. Intima-media thickness at different arterial segments in pediatric type 1 diabetes patients and its relationship with advanced glycation end products. *Pediatr. Diabetes* **2018**, *19*, 450–456. [CrossRef]

131. Podgorski, M.; Szatko, K.; Stanczyk, M.; Pawlak-Bratkowska, M.; Fila, M.; Bieniek, E.; Tkaczyk, M.; Grzelak, P.; Lukaszewski, M. Two-Dimensional Speckle Tracking Versus Applanation Tonometry in Evaluation of Subclinical Atherosclerosis in Children with Type 1 Diabetes Mellitus. *Med. Sci. Monit.* **2019**, *25*, 7289–7294. [CrossRef] [PubMed]

132. Glackin, S.; Islam, N.; Henderson, A.M.; Dionne, J.M.; Harris, K.C.; Panagiotopoulos, C.; Devlin, A.M. Ambulatory blood pressure and carotid intima media thickness in children with type 1 diabetes. *Pediatr. Diabetes* **2020**, *21*, 358–365. [CrossRef] [PubMed]